Mohamed Ali Hussein

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 15

Top Topics

Radical Prostatectomy

Signaling Pathway

Circulating Tumor

Top Venues

Pharmaceuticals (Basel, Switzerland)

Personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Mohamed Ali Hussein, Kamyab Valinezhad, Eman Adel, Gnanasekar Munirathinam
MALAT-1 Is a Key Regulator of Epithelial-Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis. Cancers 16 (1) (2024)
Rewan Gamal Mohamed, Rania Saber, Mohamed Ali Hussein, Amira Shalaby, Nouran Yasser, Sherif Kamal, Lobna Shalaby, Mohamed Nagy
Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management. Personalized medicine (2024)
Fadya M Elgarhy, Abdallah Borham, Noha Alziny, Khlood R AbdElaal, Mahmoud Shuaib, Abobaker Salem Musaibah, Mohamed Ali Hussein, Anwar Abdelnaser
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
Fadya M Elgarhy, Abdallah Borham, Noha Alziny, Khlood R AbdElaal, Mahmoud Shuaib, Abobaker Salem Musaibah, Mohamed Ali Hussein, Anwar Abdelnaser
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
Mohamed Ali Hussein, Kamyab Valinezhad, Eman Adel, Gnanasekar Munirathinam
MALAT-1 Is a Key Regulator of Epithelial-Mesenchymal Transition in Cancer: A Potential Therapeutic Target for Metastasis. Cancers 16 (1) (2024)
Basma Hossam Abdelmonem, Noha M Abdelaal, Eman K E Anwer, Alaa A Rashwan, Mohamed Ali Hussein, Yasmin F Ahmed, Rana Khashana, Mireille M Hanna, Anwar Abdelnaser
Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines 12 (7) (2024)
Rewan Gamal Mohamed, Rania Saber, Mohamed Ali Hussein, Amira Shalaby, Nouran Yasser, Sherif Kamal, Lobna Shalaby, Mohamed Nagy
Optimizing vancomycin therapeutic drug monitoring compliance in pediatric oncology: towards personalized medication management. Personalized medicine 21 (4) (2024)
Basma Hossam Abdelmonem, Noha M Abdelaal, Eman K E Anwer, Alaa A Rashwan, Mohamed Ali Hussein, Yasmin F Ahmed, Rana Khashana, Mireille M Hanna, Anwar Abdelnaser
Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines 12 (7) (2024)
Basma Hossam Abdelmonem, Noha M Abdelaal, Eman K E Anwer, Alaa A Rashwan, Mohamed Ali Hussein, Yasmin F Ahmed, Rana Khashana, Mireille M Hanna, Anwar Abdelnaser
Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. Biomedicines 12 (7) (2024)
Fadya M Elgarhy, Abdallah Borham, Noha Alziny, Khlood R AbdElaal, Mahmoud Shuaib, Abobaker Salem Musaibah, Mohamed Ali Hussein, Anwar Abdelnaser
From Drug Discovery to Drug Approval: A Comprehensive Review of the Pharmacogenomics Status Quo with a Special Focus on Egypt. Pharmaceuticals (Basel, Switzerland) 17 (7) (2024)
Angela Samy, Mohamed Ali Hussein, Gnanasekar Munirathinam
Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway. Journal of cancer research and clinical oncology (2023)
Mohamed Ali Hussein, Gnanasekar Munirathinam
Androgen Receptor Signaling in Prostate Cancer Genomic Subtypes. Cancers 15 (20) (2023)
Mohamed Ali Hussein, Gnanasekar Munirathinam
MicroRNAs in Prostate Cancer: Implications for Treatment Response and Therapeutic Targets. Cancers 15 (20) (2023)
Mohamed Ali Hussein, Gnanasekar Munirathinam
Gene Expression and DNA Methylation as Prognostic Markers in Metastatic Castration-Resistant Prostate Cancer: Analysis of Circulating Tumor Cells and Paired Plasma-Derived Exosomes. Cancers 15 (22) (2023)
Reshmii Venkatesan, Mohamed Ali Hussein, Leah Moses, Jennifer S Liu, Salman R Khetani, Alexander Kornienko, Gnanasekar Munirathinam
Polygodial, a Sesquiterpene Dialdehyde, Activates Apoptotic Signaling in Castration-Resistant Prostate Cancer Cell Lines by Inducing Oxidative Stress. Cancers 14 (21) (2022)